Polymyxin B haemoperfusion treatment for respiratory failure and hyperferritinaemia due to COVID-19

12Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A 69-year-old man with a history of type 2 diabetes and high blood pressure was diagnosed with coronavirus disease 2019 (COVID-19). He had hyperferritinaemia and respiratory failure. Despite the initiation of favipiravir and high-dose corticosteroid and ceftriaxone, his respiratory failure progressed and serum ferritin levels increased. After polymyxin B-immobilized fibre column direct haemoperfusion (PMX-DHP) therapy, there was improvement of the respiratory failure and hyperferritinaemia. We report the first case of COVID-19-induced hyperferritinaemia and severe respiratory failure successfully treated by PMX-DHP.

Author supplied keywords

Cite

CITATION STYLE

APA

Ishiwari, M., Togashi, Y., Takoi, H., Kikuchi, R., Kono, Y., & Abe, S. (2020). Polymyxin B haemoperfusion treatment for respiratory failure and hyperferritinaemia due to COVID-19. Respirology Case Reports, 8(9). https://doi.org/10.1002/rcr2.679

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free